The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis.


Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
08 2023
Historique:
received: 25 01 2023
revised: 03 04 2023
accepted: 22 05 2023
medline: 1 8 2023
pubmed: 20 6 2023
entrez: 19 6 2023
Statut: ppublish

Résumé

This meta-analysis conducted a comprehensive analysis of research investigating the correlation between HER2 expression levels and treatment outcomes in early-stage triple-negative breast cancer (TNBC) patients. We systematically searched major databases for studies published up to January 01, 2023. The data from various studies examined the relationship between HER2-zero and HER2-low tumors in terms of pathological complete response (pCR) rates, disease-free survival (DFS), and overall survival (OS) outcomes. The odds ratio (OR) and 95% confidence interval (CI) by the number of events were calculated using the Mantel-Haenszel method to analyze pCR. The hazard ratio and 95% CI were calculated using the inverse variance method for DFS and OS. In all comparisons, I

Identifiants

pubmed: 37336652
pii: S1526-8209(23)00137-4
doi: 10.1016/j.clbc.2023.05.015
pii:
doi:

Types de publication

Systematic Review Meta-Analysis Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

567-575

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure All authors have declared no conflicts of interest.

Auteurs

Yakup Ergun (Y)

Department of Medical Oncology, Batman World Hospital, Batman, Turkey. Electronic address: dr.yakupergun@gmail.com.

Baran Akagunduz (B)

Department of Medical Oncology, Binali Yıldırım University Mengücek Gazi Training and Research Hospital, Erzincan, Turkey.

Cengiz Karacin (C)

Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.

Sema Turker (S)

Department of Medical Oncology, VM Medical Park Maltepe Hospital, Istanbul, Turkey.

Gokhan Ucar (G)

Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH